# KROCUS (NCT05756153)

> A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

No report yet. It can be ordered.

- Drugs tested: fulzerasib plus cetuximab
- Indication: previously untreated advanced KRAS G12C-mutated NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05756153
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Genfleet Therapeutics (Shanghai) Inc.
- Conditions: Advance Non-small Cell Lung Cancer
- Interventions: GFH925; Cetuximab
- Enrollment: 47
- Primary outcome: Phase Ib: adverse events
- Primary outcome: Phase II: objective response rate

## Some of the questions raised in the 21 indexed sources

_Automated from all 21 indexed sources (Nov 2023 – Apr 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether a chemotherapy-free fulzerasib-cetuximab regimen can replace PD-1-based first-line therapy, alone or with chemotherapy
- Whether the combination controls brain metastases in KRAS G12C NSCLC
- Whether PD-L1 or EGFR expression predicts benefit from fulzerasib plus cetuximab
- Whether cetuximab blocks EGFR feedback and delays adaptive resistance to KRAS G12C inhibition

## Indexed commentary on KROCUS so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 17 posts on X
- 2 YouTube videos
- 2 podcast episodes

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=krocus-nct05756153

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05756153", "email": "<work email>"}; the inbox owner confirms by the emailed link.
